Correction to: MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.

Choudhary, G S; Al-Harbi, S; Mazumder, S; Hill, B T; Smith, M R; Bodo, J; Hsi, E D; Almasan, A

Choudhary, G S; Al-Harbi, S; Mazumder, S; Hill, B T; Smith, M R; Bodo, J; Hsi, E D; Almasan, A.

Afiliação

Choudhary GS; Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 44195, USA.
Al-Harbi S; Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, 44106, USA.
Mazumder S; Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 44195, USA.
Hill BT; Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 44195, USA.
Smith MR; Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, 44195, USA.
Bodo J; Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, 44195, USA.
Hsi ED; Department of Clinical Pathology, Institute of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, OH, 44195, USA.
Almasan A; Department of Clinical Pathology, Institute of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, OH, 44195, USA.

Cell Death Dis ; 15(7): 526, 2024 Jul 24.

Article em En | MEDLINE | ID: mdl-39048569

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cell Death Dis Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google